Potential use of miR-21-5p as a marker for cardiovascular disease progression after COVID-19

Ruslan I. Litvinenko; Литвиненко Руслан Игоревич; Ruslan I. Litvinenko; Arkady V. Yazenok; Язенок Аркадий Витальевич; Arkady V. Yazenok; Sergey V. Gaiduk; Гайдук Сергей Валентинович; Sergey V. Gaiduk; Pavel A. Slizhov; Слижов Павел Алексеевич; Pavel A. Slizhov; Ruslan I. Glushakov; Глушаков Руслан Иванович; Ruslan I. Glushakov

doi:10.17816/brmma634527

微核糖核酸miR-21-5p作为新型冠状病毒感染后患者心血管疾病变发展标志物的使用可能性

作者: Litvinenko R.I.¹, Yazenok A.V.¹, Gaiduk S.V.¹, Slizhov P.A.¹, Glushakov R.I.¹^,2
隶属关系:
1. Kirov Military Medical Academy
2. Saint Petersburg State Pediatric Medical University
期: 卷 26, 编号 4 (2024)
页面: 579-586
栏目: Original Study Article
##submission.dateSubmitted##: 23.07.2024
##submission.dateAccepted##: 01.10.2024
##submission.datePublished##: 18.12.2024
URL: https://journals.eco-vector.com/1682-7392/article/view/634527
DOI: https://doi.org/10.17816/brmma634527
ID: 634527

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅或者付费存取

详细
全文:
作者简介
参考
补充文件
统计

详细

对120例感染新型冠状病毒后出现心血管病变的患者进行了血液中循环miR-21-5p的水平研究。根据纳入和非纳入标准，选择了6组患者，每组20名曾感染过新型冠状病毒，且需要住院治疗的患者。评估血液中微核糖核酸miR-21-5p水平作为新型冠状病毒感染后，患者心血管病变发展/恶化的生物标志物的意义。根据先前已证实存在冠心病、高血压和动脉粥样硬化，以及未确诊心血管病变的原则进行分组。患者还被分为循环系统疾病恶化或初次发病和无循环系统疾病的两组。在循环系统病理学验证范围内，对所有患者在新型冠状病毒感染前后进行了检查。当将最初证实的冠心病恶化或未恶化的组与最初没有心血管疾病的组进行比较时，发现微核糖核酸miR-21-5p水平存在统计学上的显著差异。在对最初证实的高血压和动脉粥样硬化组相比时，心血管病变病程没有统计学上的显著差异。由此可见，测定血液中的微核糖核酸miR-21-5p是评估冠心病病程的一种很有前景的生物标志物，包括新型冠状病毒感染后的患者。这种方法与根据临床现象，以及实验室数据和仪器研究法得出的冠心病病程的评估结果相互关联。对心血管病变患者进行更大样本的进一步研究，以及随着时间的推移动态监测微核糖核酸miR-21-5p的表达水平，可能会增加这一生物标志物的信息量，并有助于为这种病症患者做出进一步动态监测的临床决策，达到减少不良并发症的目的。

关键词

新型冠状病毒感染, 动脉粥样硬化, 高血压, 冠心病, 实验室诊断, 微核糖核酸 miR-21-5p, 分子遗传学研究, 循环系统

全文:

俄罗斯联邦, Saint Petersburg; Saint Petersburg

参考

Bichurin DR, Atmaikina OV, Cherepanova OA. Cardiovascular diseases. Regional aspect. International Research Journal. 2023;8(134). doi: 10.23670/IRJ.2023.134.103
Andreenko AA, Andreichuk YuV, Arsent’ev VG, et al. Infection caused by SARS-COV-2. Kryukov EV, ed. Saint Petersburg; 2023. 260 p. (In Russ.) EDN: QFKFPFCOVID-19
Berezovskaya GA, Petrishchev NN, Volkova EV, et al. Defeat of the cardiovascular system in the new coronavirus infection COVID-19. Cardiology: news, opinion, training. 2022;10(4):37–47. doi: 10.33029/2309-1908-2022-10-4-37-47
Melnikova LV, Lokhina TV, Berenstein NV, and others. Cardiovascular consequences of COVID-19: pathogenesis, diagnosis and treatment. Lechaschi Vrach. 2021;(7):8–13. (In Russ.) doi: 10.51793/OS.2021.24.7.002
Kryukov EV, Trishkin DV, Salukhov VV, et al. Experience of military medicine in the fight against the new coronavirus infection. Vestnik Rossijskoj Akademii Nauk. 2022;92(7):699–706. (In Russ.) EDN: HIPURN doi: 10.1134/S1019331622040050
Felekkis K, Touvana E, Stefanou C, et al. MicroRNAs: A newly described class of encoded molecules that play a role in health and disease. Hippokratia. 2010;14(4):236–240.
Gumilevskiy BYu, Moskalev AV, Gumilevskay OP, et al. Features of immunopathogenesis of a new coronavirus infection. Bulletin of the Russian Military Medical Academy. 2021;23(1):187–198. doi: 10.17816/brmma.63654
Romaine SPR, Tomaszewski M, Condorelli G, et al. MicroRNAs in cardiovascular disease: An introduction for clinicians. Heart. 2015;101(12):921–928. doi: 10.1136/heartjnl–2013–305402
Peters LJF, Biessen EAL, Hohl M, et al. Small things matter: Relevance of microRNAs in cardiovascular disease. Front Physiol. 2020;11:1–14. doi: 10.3389/fphys.2020.00793
Marchi R, Sugita B, Centa A, et al. The role of microRNAs in modulating SARS-CoV-2 infection in human cells: A systematic review. Infect Genet Evol. 2021;91:104832. doi: 10.1016/j.meegid.2021.104832
Garg A, Seeliger B, Derda AA, et al. Circulating cardiovascular microRNAs in critically ill COVID-19 patients. Eur J Heart Fail. 2021;23(3):468–475. doi: 10.1002/ejhf.2096
Pieri M, Vayianos P, Nicolaidou V, et al. Alterations in circulating miRNA levels after infection with SARS-CoV-2 could contribute to the development of cardiovascular diseases: What We Know So Far. Int J Mol Sci. 2023;24(3):1–14. doi: 10.3390/ijms24032380
Chistiakov DA, Sobenin IA, Orekhov AN, et al. Human miR-221/222 in physiological and atherosclerotic vascular remodeling. BioMed. Res. Int. 2015;2015:354517. doi: 10.1155/2015/354517
Cengiz M, Yavuzer S, Avci BK, et al. Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension. Clin Exp Hypertens. 2015;37(8):643–649. doi: 10.3109/10641963.2015.1036064
Zhu N, Zhang D, Chen S, et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis. 2011;215(2):286–293. doi: 10.1016/j.atherosclerosis.2010.12.024
Kumar A, Fausto A. Robbins and Cotran in pathologic basis of disease. 10th ed. Spain: Elsevier España, S.L.U.; 2020. Р. 1392.
Sanlialp M, Dodurga Y, Uludag B, et al. Peripheral blood mononuclear cell microRNAs in coronary artery disease. J Cell Biochem. 2020;121(4):3005–3009. doi: 10.1002/jcb.29557
Chen Z, Song S, Zhu J, et al. Regulatory mechanism of MiR-21 in formation and rupture of intracranial aneurysm through JNK signaling pathway-mediated inflammatory response. Int J Clin Exp Pathol. 2020;13(7):1834–1841. doi: 10.3389/fgene.2022.875007
Ren W, Hou J, Yang C, et al. Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery. J Exp Clin Cancer Res. 2019;38(1):62. doi: 10.1186/s13046-019-1027-0